FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Ropinirole Hydrochloride (Requip) Tablets
Status: Discontinuation
»Therapeutic Categories: Neurology

Expand all

GlaxoSmithKline (New 12/19/2018)

Company Contact Information:
908-293-5330

Presentation Posting Date Related Information
Ropinirole Hydrochloride (Requip) Tablets, 0.25 mg, 100 count bottles (NDC 0007-4890-20) 12/19/2018 A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately April 2019.
Ropinirole Hydrochloride (Requip) QUIP Tablets, 0.5 mg, 100 count bottles (NDC 0007-4891-20) 12/19/2018 A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately May 2019.
Ropinirole Hydrochloride (Requip) Tablets, 1 mg, 100 count bottles (NDC 0007-4892-20) 12/19/2018 A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately January 2019.
Ropinirole Hydrochloride (Requip) Tablets, 2 mg, 100 count bottles (NDC 0007-4893-20) 12/19/2018 A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately January 2019.
Ropinirole Hydrochloride (Requip) Tablets, 3 mg, 100 count bottles (NDC 0007-4895-20) 12/19/2018 A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately April 2019.
Ropinirole Hydrochloride (Requip) Tablets, 4 mg, 100 count bottles (NDC 0007-4896-20) 12/19/2018 A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately May 2019.
Ropinirole Hydrochloride (Requip) Tablets, 5 mg, 100 count bottles (NDC 0007-4894-20) 12/19/2018 A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately March 2019.
Ropinirole Hydrochloride (Requip) XL Tablets, 2 mg, 30 count bottles (NDC 0007-4885-13) 12/19/2018 A business decision was made to discontinue manufacture of the drug product. The anticipated final date of availability to patients is approximately March 2019.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English